![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Long-Acting Cabotegravir + Rilpivirine Injection Site Reactions:
Pooled Week 96 Results
|
|
|
AIDS 2022 July 29-Aug 1 Montreal
Nadine Chamay1, Emilie Elliot1, Samia Dakhia1, Joseph W. Polli2, Louise Garside3, Paula Teichner2, Shanker Thiagarajah3, Ronald D'Amico2,
Rodica Van Solingen-Ristea4, Eileen Birmingham5, Bryan Baugh6, Jean van Wyk1
1ViiV Healthcare, Brentford, United Kingdom; 2ViiV Healthcare, Research Triangle Park, NC, United States; 3GlaxoSmithKline, London, United Kingdom; 4Janssen Research & Development, Beerse, Belgium
5Janssen Research & Development, Raritan, NJ, United States; 6Janssen Research & Development, Titusville, NJ, United States
![0805221copy](../images/080622/080622-6/0805221copy.gif)
![0805222copy](../images/080622/080622-6/0805222copy.gif)
![0805223copy](../images/080622/080622-6/0805223copy.gif)
![0805224copy](../images/080622/080622-6/0805224copy.gif)
![0805225copy](../images/080622/080622-6/0805225copy.gif)
![0805226copy](../images/080622/080622-6/0805226copy.gif)
![0805227copy](../images/080622/080622-6/0805227copy.gif)
![0805228copy](../images/080622/080622-6/0805228copy.gif)
![0805229copy](../images/080622/080622-6/0805229copy.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|